ENO1 Links Glycolytic Metabolism, HBV Replication, and Immune Evasion in HBV-Related Hepatocellular Carcinoma

Liver cancer is a formidable disease, but for millions of people around the world, its story begins with a virus. Hepatitis B is an infection that can linger in the liver for decades, slowly turning healthy tissue into a site of chronic inflammation and, eventually, cancer. While doctors have made great strides in treating this disease, a significant challenge remains: the cancer cells are not just growing out of control; they are also hiding from the body's immune system and rewiring their internal chemistry to survive. To understand how these cells thrive, scientists must look at the tiny molecular machines inside them that manage energy and interact with the virus. One such machine is an enzyme called ENO1. Think of it as a specialized worker in a factory, responsible for breaking down sugar to provide the fuel and building blocks a cell needs to grow. For a long time, researchers knew this worker was busy in cancer cells, but they did not fully understand how it helped the virus persist or how it might be tricking the immune system into standing down.

A team of researchers from Ningxia Medical University in China set out to map the full role of this enzyme in liver cancer driven by the Hepatitis B virus. They started by looking at vast amounts of genetic data from thousands of patients, searching for patterns that linked the amount of ENO1 in a tumor to how the disease behaved. They found that the enzyme was present in much higher amounts in liver cancer tissue than in healthy liver tissue. More specifically, the highest levels were found in tumors caused by the Hepatitis B virus. When they looked at the patients' medical records, a clear picture emerged: those with the most ENO1 in their tumors had more aggressive disease, with cancer that had spread into blood vessels and a lower chance of long-term survival. This suggested that the enzyme was not just a bystander but a key player in making the cancer more dangerous.

The researchers then turned their attention to the immune system, asking why the body's defenses were failing to stop these high-ENO1 tumors. They discovered that tumors with high levels of the enzyme were surrounded by a different kind of immune environment. Instead of being packed with the immune cells that hunt down cancer, these tumors were filled with cells that tend to suppress the immune response. The genetic profile of these tumors also showed a high expression of "checkpoints," which are like molecular brakes that tell immune cells to stop attacking. The researchers used computer models to predict how these tumors would respond to modern immunotherapy, and the results were sobering: the high-ENO1 tumors were predicted to be much harder to treat with current immune-boosting drugs because they had effectively built a shield around themselves.

To prove that the enzyme was actually causing these changes, the scientists moved from computer data to the laboratory bench. They worked with liver cancer cells that were actively producing the Hepatitis B virus. Using a precise molecular tool, they silenced the gene that makes ENO1, effectively turning off the enzyme in these cells. The results were immediate and dramatic. Without the enzyme, the cancer cells stopped growing as fast, struggled to form new colonies, and lost their ability to move and invade other tissues. They also began to die off at a higher rate. Crucially, the virus itself suffered. When the enzyme was turned off, the amount of viral DNA inside the cells dropped, and the production of viral proteins and antigens that the virus uses to spread was significantly reduced. This showed that the enzyme was not just helping the cancer grow; it was actively supporting the virus's ability to replicate.

The team also investigated the internal chemistry of these cells to understand how the enzyme was doing its work. They found that when ENO1 was active, the cells were consuming large amounts of sugar and producing high levels of lactate, a byproduct of rapid energy production. This process, known as glycolysis, is a hallmark of aggressive cancer. When the enzyme was silenced, this metabolic engine sputtered. The cells could not process sugar efficiently, and their internal balance of antioxidants was disrupted. This suggests that the enzyme is a central hub, connecting the virus's need for energy and building blocks with the cancer cell's ability to grow and hide. By driving this metabolic process, the enzyme creates an environment that is hostile to the immune system, likely by making the area around the tumor too acidic and nutrient-poor for immune cells to function properly.

The study concludes that ENO1 acts as a critical link between the virus, the cancer's metabolism, and the immune system's failure. It is a molecule that helps the Hepatitis B virus maintain its presence while simultaneously helping the cancer cell grow and evade detection. While the researchers did not test new drugs in this study, their findings point to a new way of thinking about treatment. If scientists can find a way to block this specific enzyme, it might be possible to starve the virus, slow the cancer's growth, and potentially make the tumor more visible to the immune system again. The work highlights that in the complex battle against liver cancer, targeting the metabolic machinery that supports both the virus and the tumor could be a vital strategy for improving outcomes for patients.